Showing 3061-3070 of 3288 results for "".
- Scleroderma Foundation to Honor Genentech's Dr. Jeffrey Siegel for Scientific Contributionshttps://practicaldermatology.com/news/scleroderma-foundation-to-honor-genentechs-dr-jeffrey-siegel-for-scientific-contributions/2458864/Dr. Jeffrey Siegel, Senior Group Medical Director of Immunology at Genentech, will be honored by the Scleroderma Foundation of Southern California with the Spirit of Leadership Award at their 17th annual “Key to a Cure” gala, which will be held on Saturday, Octobe
- Report: Prescription Dermatological Drug Market Exceeds 21 Billion Dollarshttps://practicaldermatology.com/news/report-prescription-dermatological-drug-market-exceeds-21-billion-dollars/2458870/The worldwide market for prescription dermatological drugs exceeded $21 billion last year, according to a report from Kalorama Information. The market research firm said field of dermatology is currently experiencing a busy and interesting period and, as a result, the range of therapeutic options
- FDA Warns of Severe Adverse Events with Application of Picato (ingenol mebutate) Gel; Requires Label Changeshttps://practicaldermatology.com/news/fda-warns-of-severe-adverse-events-with-application-of-picato-ingenol-mebutate-gel-requires-label-changes/2458878/The FDA released a Drug Safety Communication to warn about reports of severe allergic reactions and herpes zoster (shingles) associated with the use of Picato gel (ingenol mebutate), which is approved to treat actinic keratosis. The FDA said it also received reports of cases involving sev
- Costs, Uncertainty May Cause Consumers to Delay Cosmetic Procedures: ASDShttps://practicaldermatology.com/news/costs-uncertainty-may-cause-consumers-to-delay-cosmetic-procedures-asds/2458886/Cost, fear of suboptimal results, and uncertainty over choosing a provider are the key concerns that may deter prospective patients from receiving cosmetic treatments, new findings from the 2015 American Society for Dermatologic Surgery Consumer Survey on Cosmetic Dermatologic Procedures sh
- Simulated Patient Encounter Part of Summer AAD Programhttps://practicaldermatology.com/news/simulated-patient-encounter-part-of-summer-aad-program/2458888/Simulated patient encounters have come to the American Academy of Dermatology's summer meeting, offering a unique, hands-on educational experience for attendees. Speaking to Seemal Desai, MD for DermTube.com's coverage of the 2015 Summer Meeting of the AAD in New York City, Kanade Shinkai
- Brickell Biotech Appoints Patricia Walker, MD, PhD as President and CSOhttps://practicaldermatology.com/news/brickell-biotech-appoints-patricia-walker-md-phd-as-president-and-cso/2458912/Patricia Walker, MD, PhD has joined Brickell Biotech, Inc. as President and Chief Scientific Officer. Dr. Walker, a board-certified dermatologist specializing in medical and aesthetic dermatology, most recently served as the Chief Medical Officer for Kythera Biopharmaceuticals, Inc. Over
- Unilever to Acquire Muradhttps://practicaldermatology.com/news/unilever-to-acquire-murad/2458916/Unilever has signed an agreement to acquire Murad. This follows the recent acquisitions of Dermalogica, Kate Somerville, and REN, which jointly position Unilever as a key player in the personal care prestige segment. Murad was founded in 1989 in Los Angeles. Howard Murad MD, a dermatologi
- FDA Grants Breakthrough Therapy Designation for Actemra in Systemic Sclerosishttps://practicaldermatology.com/news/fda-grants-breakthrough-therapy-designation-for-actemra-in-systemic-sclerosis/2458929/Genentech, a member of the Roche Group, was granted FDA Breakthrough Therapy Designation status for Actemra® (tocilizumab) for systemic sclerosis, also known as scleroderma. This designation is intended to expedite the development and review of medicines with early signals of poten
- Merck's Pembrolizumab Demonstrates Positive Results in Phase III Study for Advanced Melanomahttps://practicaldermatology.com/news/mercks-pembrolizumab-demonstrates-positive-results-in-phase-iii-study-for-advanced-melanoma/2458959/Merck announced results from the randomized, pivotal Phase III study, KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the study, pembrolizumab was statistically superior to ipilimumab for progression-free survival (PFS), overall survival (OS), and overall response rate (ORR).
- CareCredit Hosts Free Webinar on How to Host Successful Patient Eventshttps://practicaldermatology.com/news/carecredit-hosts-free-webinar-on-how-to-host-successful-patients-events/2458975/CareCredit will be sponsoring a free webinar to all aesthetic providers on how to host successful patient events. The webinar, How to Host Events That Bring Real Results: The Dos, Don’ts, and Definites, will be presented by Karen Zupko, President of Karen Zupko & Associate